7ZT Share Price Performance
€0.51
0.16 (46.86%)
Price €0.51
Share Price€0.51
Hamlet BioPharma AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
7ZT Community Narratives
There are no narratives available yet.
Recent 7ZT News & Updates
Hamlet BioPharma AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 14, 2025
- Earnings per share (EPS)
- -0.30
- Gross Margin
- 100.00%
- Net Profit Margin
- -26,270.61%
- Debt/Equity Ratio
- 0%
Hamlet BioPharma AB (publ) Competitors
Snowflake Analysis
About 7ZT
- Founded
- 1999
- Employees
- 8
- CEO
- WebsiteView website
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. The company was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. Hamlet BioPharma AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) is a subsidiary of Linnane Pharma AB.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Swedish Market Performance
- 7 Days: 1.7%
- 3 Months: 2.4%
- 1 Year: -0.5%
- Year to Date: 2.9%
The market is up 1.7% over the last week, with the Industrials sector leading the way, up 2.6%. In the last 12 months, the market has been flat. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›